LEVOMILNACIPRAN HYDROCHLORIDE

Post-LOE

levomilnacipran hydrochloride

Aurobindo Pharma

ANDAORALCAPSULE, EXTENDED RELEASE

Approved

Feb 2019

Lifecycle

Post-LOE

Competitive Pressure

30/100

Data completeness

3/8 — Basic

LEVOMILNACIPRAN HYDROCHLORIDE (levomilnacipran hydrochloride) by Aurobindo Pharma is unknown, but is thought to be related to the potentiation of serotonin and norepinephrine in the central nervous system, through inhibition of reuptake at serotonin and norepinephrine transporters. Approved for major depressive disorder (mdd) in adults (). First approved in 2019.

Drug data last refreshed 19h ago

Mechanism of Action

unknown, but is thought to be related to the potentiation of serotonin and norepinephrine in the central nervous system, through inhibition of reuptake at serotonin and norepinephrine transporters. Non-clinical studies have shown that levomilnacipran is a potent and selective serotonin and…

Indications (1)

Major Depressive Disorder (MDD) in adults ()

Company

Worked on LEVOMILNACIPRAN HYDROCHLORIDE at Aurobindo Pharma? Share your interview experience or compensation data (+7 days Pro)

Data Sources

Drug label: DailyMed / FDA
Clinical trials: ClinicalTrials.gov
Patent data: FDA Orange Book
Spending data: CMS Medicare

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.